Dr. Pasi A. Jänne

Doctor Overview

Dr. Pasi A. Jänne is a thoracic medical oncologist at the Dana-Farber Cancer Institute. He also is a professor at Harvard Medical School and the director of the Lowe Center for Thoracic Oncology, as well as director of the Belfer Center for Applied Cancer Science. Dr. Jänne’s main research interests include the therapeutic relevance of oncogenic alterations in lung cancer. He is affiliated with the cancer genetics and lung cancer programs at Dana-Farber/Harvard Cancer Center.

Dr. Jänne has contributed to a number of peer-reviewed journals as an author and co-author. Some of those publications include The New England Journal of Medicine, Oncology, The Journal of the National Cancer Institute, Science, and Cancer Research.

Doctor Fast Facts

Main Specialty: Thoracic Oncology

Other Interests & Specialties: Epidermal growth factor receptor targeted therapies, lung cancer, targeted therapies and translational medicine.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Certification in Medical Oncology, George P. Canellos Award for Excellence in Clinical Investigation and Patient Care, American Society of Clinical Oncology’s Merit Award, Hope Now Award for Lung Cancer Research, Team Science Award, Richard and Hinda Rosenthal Memorial Award, Research Excellence Award

Education & Experience:

• Medical Degree from University of Pennsylvania School of Medicine
• Residency in Internal Medicine at Brigham and Women’s Hospital, Internal Medicine
• Fellowship in Hematology & Oncology at Dana-Farber/Partners Cancer Care

Publications

Imaging of lung cancer in the era of molecular medicine. Academic Radiology. April 2011;18(4): 424-36. doi: 10.1016/j.acra.2010.10.020

Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-Term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. December 2018. doi: 10.1002/cncr.31891

Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Research. September 2002; 62(18): 5242-7.

Mesothelioma Clinical Trials by Pasi A. Jänne, MD, PhD

Eligible mesothelioma patients may qualify for participation in a clinical trial that is testing a novel therapy for their disease. See below for any clinical trials that Dr. Jänne may be associated with:

Unfortunately, we could not locate any active mesothelioma clinical trials for Dr. Pasi A. Jänne. Clinical trials are important for exploring new treatment options and improving patient outcomes.

Here are some other websites that might help you locate mesothelioma-specific clinical trials:

• National Cancer Institute (NCI) Clinical Trials Database – NCI provides a comprehensive list of clinical trials across the U.S. Trials can be searched for based on location, treatment type and eligibility.
• ClinicalTrials.gov – This website hosts the U.S. government's database of clinical trials. You can find specific mesothelioma trials by searching with relevant keywords, such as "mesothelioma," "asbestos-related cancer" or "pleural mesothelioma."
• Mesothelioma Applied Research Foundation – The Mesothelioma Applied Research Foundation funds mesothelioma research and has an on-staff nurse available to discuss clinical trials.